Letter to Patients


Dear PWS Community,

As you may have seen in a press release on July 19, 2016, Zafgen announced that the company has made the difficult decision to cease development of beloranib in Prader-Willi syndrome (PWS).

CLICK HERE to read the full letter.


Zafgen is a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders.

Learn More